RATIONALE: One of the most often reported cognitive deficits of acute cannabis administration is an impaired recall of previously learned information. OBJECTIVE: The aim of the present study was to determine whether cannabis-induced memory impairment in humans is mediated via glutamatergic or cholinergic pathways. METHODS:Fifteen occasional cannabis users participated in a double-blind, placebo-controlled, six-way cross-over study. On separate test days, subjects received combinations of pretreatment (placebo, vardenafil 20 mg or rivastigmine 3 mg) and treatment (placebo or 1,376 mg cannabis/kg body weight). Cognitive tests were administered immediately after inhalation of treatment was finished and included measures of memory (visual verbal learning task, prospective memory test, Sternberg memory test), perceptual-motor control (critical tracking task), attention (divided attention task) and motor impulsivity (stop signal task). RESULTS: The results of this study demonstrate that subjects under the influence of cannabis were impaired in all memory tasks, in critical tracking, divided attention and the stop signal task. Pretreatment with rivastigmine attenuated the effect of cannabis on delayed recall and showed a trend towards significance on immediate recall. When cannabis was given in combination with vardenafil, there were no significant interaction effects in any of the tasks. CONCLUSIONS: The present data therefore suggest that acetylcholine plays an important role in cannabis-induced memory impairment, whereas similar results for glutamate have not been demonstrated in this study.
RCT Entities:
RATIONALE: One of the most often reported cognitive deficits of acute cannabis administration is an impaired recall of previously learned information. OBJECTIVE: The aim of the present study was to determine whether cannabis-induced memory impairment in humans is mediated via glutamatergic or cholinergic pathways. METHODS: Fifteen occasional cannabis users participated in a double-blind, placebo-controlled, six-way cross-over study. On separate test days, subjects received combinations of pretreatment (placebo, vardenafil 20 mg or rivastigmine 3 mg) and treatment (placebo or 1,376 mg cannabis/kg body weight). Cognitive tests were administered immediately after inhalation of treatment was finished and included measures of memory (visual verbal learning task, prospective memory test, Sternberg memory test), perceptual-motor control (critical tracking task), attention (divided attention task) and motor impulsivity (stop signal task). RESULTS: The results of this study demonstrate that subjects under the influence of cannabis were impaired in all memory tasks, in critical tracking, divided attention and the stop signal task. Pretreatment with rivastigmine attenuated the effect of cannabis on delayed recall and showed a trend towards significance on immediate recall. When cannabis was given in combination with vardenafil, there were no significant interaction effects in any of the tasks. CONCLUSIONS: The present data therefore suggest that acetylcholine plays an important role in cannabis-induced memory impairment, whereas similar results for glutamate have not been demonstrated in this study.
Authors: Alireza Atri; Seth Sherman; Kenneth A Norman; Brenda A Kirchhoff; Marlene M Nicolas; Michael D Greicius; Steven C Cramer; Hans C Breiter; Michael E Hasselmo; Chantal E Stern Journal: Behav Neurosci Date: 2004-02 Impact factor: 1.912
Authors: Matthijs G Bossong; J Martijn Jansma; Hendrika H van Hell; Gerry Jager; Erik Oudman; Emi Saliasi; René S Kahn; Nick F Ramsey Journal: Biol Psychiatry Date: 2012-02-17 Impact factor: 13.382
Authors: T Jordan Walter; Nina Pocuca; Jared W Young; Mark A Geyer; Arpi Minassian; William Perry Journal: Psychiatry Res Date: 2020-12-29 Impact factor: 3.222
Authors: Caesar M Hernandez; Caitlin A Orsini; Shelby L Blaes; Jennifer L Bizon; Marcelo Febo; Adriaan W Bruijnzeel; Barry Setlow Journal: J Psychopharmacol Date: 2020-12-09 Impact factor: 4.562
Authors: Nadia Rpw Hutten; Kim Pc Kuypers; Janelle Hp van Wel; Eef L Theunissen; Stefan W Toennes; Robbert-Jan Verkes; Johannes G Ramaekers Journal: J Psychopharmacol Date: 2018-06-27 Impact factor: 4.153